AC
TRDA icon

AXQ Capital’s Entrada Therapeutics TRDA Stock Holding History

AXQ Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,650
Closed -$109K – 1261
2025
Q4 		$109K Sell
10,650
-920
-8% -$7.75K 0.02% 641
2025
Q3 		$67.1K Buy
+11,570
New +$67.7K 0.03% 536

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AXQ Capital's TRDA Position: Q1 2026 in Review

AXQ Capital sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 10,650 shares — an estimated $109K sold.

AXQ Capital first reported a position in TRDA in Q3 2025 and held it in 2 quarters. The position peaked at $109K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • AXQ Capital reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 10,650 Entrada Therapeutics shares in Q1 2026, an estimated $109K.
  • AXQ Capital first reported a position in Entrada Therapeutics in Q3 2025 and held it in 2 quarters.
  • AXQ Capital's Entrada Therapeutics position peaked at $109K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.